{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:26:23Z","timestamp":1764761183110,"version":"3.46.0"},"reference-count":35,"publisher":"Becaris Publishing Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Pimavanserin (PIM) is the only US FDA-approved atypical antipsychotics (AAPs) for the treatment for hallucinations and delusions associated with Parkinson\u2019s disease psychosis (PDP). In addition to demonstrating symptom improvements in clinical trials, PIM appears to consistently show favorable outcomes among published real-world evidence (RWE) studies compared with off-label AAPs (e.g., quetiapine [QUE]). A comprehensive review of these RWE studies was conducted to summarize the overall benefits of PIM among PDP patients residing in community or nursing home\/long-term care (NH\/LTC) settings.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A literature review of published comparative RWE studies of PIM among PDP patients from 1 January 2017 to 1 April 2025 was conducted. Eligible studies examined the following outcomes in community and NH\/LTC settings: clinical (e.g., falls, fractures), adherence (e.g., discontinuations), all-cause and psychiatric (psych)-related healthcare resource use (e.g., hospitalizations, emergency room (ER) visits, office visits, etc.), and mortality.\n                    <jats:bold>Results:<\/jats:bold>\n                    Sixteen RWE studies of PIM versus other-AAPs or QUE and PIM nonusers were included for review. In these studies, PIM had 20\u201337% lower all-cause and psych-related hospitalizations, 7\u201315% lower ER visits, significant delays to LTC admissions, lower rates of falls or fractures in NH\/LTC settings and lower observed rates of mortality versus other-AAPs. Similar results were found for PIM versus QUE.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    PDP patients initiating PIM versus other-AAPs or QUE were associated with lower all-cause and psychiatric healthcare resource use burden, longer community-stays and delayed NH\/LTC admissions. Additionally, PIM was associated with higher treatment compliance, fewer falls or fractures and lower overall mortality risk versus other-AAPs or QUE. PIM\u2019s favorable real-world profile versus other-AAPs or QUE across community and NH\/LTC settings complement the favorable clinical trial findings.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0129","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:18:03Z","timestamp":1761571083000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence of pimavanserin utilization among patients with Parkinson\u2019s disease psychosis: a review of real-world data that augments data from randomized controlled trials"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-1234","authenticated-orcid":false,"given":"Nazia","family":"Rashid","sequence":"first","affiliation":[{"name":"Medical Affairs, Acadia Pharmaceuticals Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-8561","authenticated-orcid":false,"given":"Ismaeel","family":"Yunusa","sequence":"additional","affiliation":[{"name":"University of South Carolina, College of Pharmacy, Columbia, SC 29208, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilesh","family":"Doshi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Acadia Pharmaceuticals Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Yakkala","sequence":"additional","affiliation":[{"name":"Anlitiks Inc., Windermere, FL 34786, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daksha","family":"Gopal","sequence":"additional","affiliation":[{"name":"Anlitiks Inc., Windermere, FL 34786, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[{"name":"Medical Affairs, Acadia Pharmaceuticals Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-0822","authenticated-orcid":false,"given":"Krithika","family":"Rajagopalan","sequence":"additional","affiliation":[{"name":"Anlitiks Inc., Windermere, FL 34786, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"9916","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled Phase III trial","volume":"383","author":"Cummings J","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled Phase III trial. Lancet 383(9916), 533\u2013540 (2014).","journal-title":"Lancet"},{"issue":"2","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1212\/CPJ.0000000000000342","article-title":"Pimavanserin: a novel therapeutic option for Parkinson disease psychosis","volume":"7","author":"Hawkins T","year":"2017","unstructured":"Hawkins T, Berman BD. Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol. Clin. Pract. 7(2), 157\u2013162 (2017).","journal-title":"Neurol. Clin. Pract."},{"issue":"4","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3233\/JPD-202047","article-title":"Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson's disease psychosis","volume":"10","author":"Isaacson SH","year":"2020","unstructured":"Isaacson SH, Coate B, Norton J, Stankovic S. Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson's disease psychosis. J. Parkinsons Dis. 10(4), 1389\u20131396 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2021.04.012","article-title":"Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients","volume":"87","author":"Isaacson SH","year":"2021","unstructured":"Isaacson SH, Ballard CG, Kreitzman DL Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. Parkinsonism Relat. Disord. 87, 25\u201331 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s13311-013-0238-x","article-title":"Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease","volume":"11","author":"Connolly B","year":"2014","unstructured":"Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics 11(1), 78\u201391 (2014).","journal-title":"Neurotherapeutics"},{"issue":"8","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinson's disease: a review","volume":"25","author":"Zahodne LB","year":"2008","unstructured":"Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 25(8), 665\u2013682 (2008).","journal-title":"Drugs Aging"},{"issue":"6","key":"e_1_3_6_9_2","first-page":"368","article-title":"Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson's disease","volume":"42","author":"Cruz MP","year":"2017","unstructured":"Cruz MP. Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson's disease. P. T. 42(6), 368\u2013371 (2017).","journal-title":"P. T."},{"issue":"7","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","author":"2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","unstructured":"2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 71(7), 2052\u20132081 (2023).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"2","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi K","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov. Disord. 34(2), 180\u2013198 (2019).","journal-title":"Mov. Disord."},{"issue":"2","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/jmahp12020009","article-title":"Real-world evidence to reinforce clinical trial evidence in health technology assessment: a critical review of real-world evidence requirements from seven countries and recommendations to improve acceptance","volume":"12","author":"Thokagevistk K","year":"2024","unstructured":"Thokagevistk K, Coppo C, Rey L Real-world evidence to reinforce clinical trial evidence in health technology assessment: a critical review of real-world evidence requirements from seven countries and recommendations to improve acceptance. J. Mark. Access Health Policy 12(2), 105\u2013117 (2024).","journal-title":"J. Mark. Access Health Policy"},{"key":"e_1_3_6_13_2","unstructured":"US Food and Drug Administration. 21st Century Cures Act. (2020). Available from: https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/21st-century-cures-act"},{"key":"e_1_3_6_14_2","unstructured":"ISPOR. Top 10 HEOR Trends. (2024). Available from: https:\/\/www.ispor.org\/heor-resources\/top-10-heor-trends"},{"issue":"4","key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3233\/JPD-213035","article-title":"Incidence, prevalence, and mortality of psychosis associated with Parkinson's disease (1991\u20132010)","volume":"12","author":"Stang CD","year":"2022","unstructured":"Stang CD, Mullan AF, Camerucci E Incidence, prevalence, and mortality of psychosis associated with Parkinson's disease (1991\u20132010). J. Parkinsons Dis. 12(4), 1319\u20131327 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"e_1_3_6_16_2","first-page":"100256","article-title":"Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis","volume":"10","author":"Isaacson SH","year":"2024","unstructured":"Isaacson SH, Pahwa R, Pagan F, Abler V, Truong D. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis. Clin. Park. Relat. Disord. 10, 100256 (2024).","journal-title":"Clin. Park. Relat. Disord."},{"issue":"3","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mdc3.13652","article-title":"Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among medicare beneficiaries with Parkinson's disease psychosis","volume":"10","author":"Alipour-Haris G","year":"2023","unstructured":"Alipour-Haris G, Armstrong MJ, Okun M, Brown JD. Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among medicare beneficiaries with Parkinson's disease psychosis. Mov. Disord. Clin. Pract. 10(3), 406\u2013414 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"1","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/13696998.2022.2152600","article-title":"Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics","volume":"26","author":"Rajagopalan K","year":"2023","unstructured":"Rajagopalan K, Rashid N, Kumar S, Doshi D. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. J. Med. Econ. 26(1), 34\u201342 (2023).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/13696998.2023.2220597","article-title":"Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries","volume":"26","author":"Rajagopalan K","year":"2023","unstructured":"Rajagopalan K, Rashid N, Doshi D. Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries. J. Med. Econ. 26(1), 769\u2013776 (2023).","journal-title":"J. Med. Econ."},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0038"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0114"},{"issue":"1","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12883-021-02265-x","article-title":"Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?","volume":"21","author":"Pham Nguyen TP","year":"2021","unstructured":"Pham Nguyen TP, Abraham DS, Thibault D, Weintraub D, Willis AW. Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?. BMC Neurol. 21(1), 240 (2021).","journal-title":"BMC Neurol."},{"issue":"1","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40801-021-00284-1","article-title":"Falls and fractures in patients with Parkinson's disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study","volume":"9","author":"Layton JB","year":"2022","unstructured":"Layton JB, Forns J, Turner ME Falls and fractures in patients with Parkinson's disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes 9(1), 9\u201322 (2022).","journal-title":"Drugs Real World Outcomes"},{"issue":"3","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40801-024-00433-2","article-title":"Falls and fractures among nursing home residents treated with pimavanserin versus other atypical antipsychotics: analysis of Medicare beneficiaries with Parkinson's disease psychosis","volume":"11","author":"Rajagopalan K","year":"2024","unstructured":"Rajagopalan K, Rashid N, Gopal D, Doshi D. Falls and fractures among nursing home residents treated with pimavanserin versus other atypical antipsychotics: analysis of Medicare beneficiaries with Parkinson's disease psychosis. Drugs Real World Outcomes 11(3), 441\u2013449 (2024).","journal-title":"Drugs Real World Outcomes"},{"issue":"13","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1212\/WNL.0000000000012601","article-title":"Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease","volume":"97","author":"Hwang YJ","year":"2021","unstructured":"Hwang YJ, Alexander GC, An H, Moore TJ, Mehta HB. Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease. Neurology 97(13), e1266\u2013e1275 (2021).","journal-title":"Neurology"},{"issue":"17","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1212\/WNL.0000000000006396","article-title":"Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine","volume":"91","author":"Moreno GM","year":"2018","unstructured":"Moreno GM, Gandhi R, Lessig SL, Wright B, Litvan I, Nahab FB. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. Neurology 91(17), 797\u2013799 (2018).","journal-title":"Neurology"},{"key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2022.08.013","article-title":"Atypical antipsychotic use and mortality risk in Parkinson disease","volume":"103","author":"Pham Nguyen TP","year":"2022","unstructured":"Pham Nguyen TP, Thibault D, Hamedani AG, Weintraub D, Willis AW. Atypical antipsychotic use and mortality risk in Parkinson disease. Parkinsonism Relat. Disord. 103, 17\u201322 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"e0278262","DOI":"10.1371\/journal.pone.0278262","article-title":"Assessing the risks of treatment in Parkinson disease psychosis: an in-depth analysis","volume":"18","author":"Longardner K","year":"2023","unstructured":"Longardner K, Wright BA, Alakkas A Assessing the risks of treatment in Parkinson disease psychosis: an in-depth analysis. PLOS One 18(1), e0278262 (2023).","journal-title":"PLOS One"},{"issue":"8","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/appi.ajp.21090876","article-title":"Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries","volume":"179","author":"Mosholder AD","year":"2022","unstructured":"Mosholder AD, Ma Y, Akhtar S Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries. Am. J. Psychiatry 179(8), 553\u2013561 (2022).","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40264-025-01543-8","article-title":"Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update","volume":"48","author":"Rao S","year":"2025","unstructured":"Rao S, McQuay LJ, Forns J Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update. Drug Saf. 48(8), 893\u2013907 (2025).","journal-title":"Drug Saf."},{"key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/CEOR.S452162","article-title":"Analysis of Medicare patients treated with pimavanserin versus other atypical antipsychotics: a cost-offset model evaluating skilled nursing facility stays and long-term care admissions in Parkinson's disease psychosis","volume":"16","author":"Rajagopalan K","year":"2024","unstructured":"Rajagopalan K, Rashid N, Yakkala V, Doshi D. Analysis of Medicare patients treated with pimavanserin versus other atypical antipsychotics: a cost-offset model evaluating skilled nursing facility stays and long-term care admissions in Parkinson's disease psychosis. Clinicoecon. Outcomes Res. 16, 149\u2013159 (2024).","journal-title":"Clinicoecon. Outcomes Res."},{"key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.parkreldis.2020.07.021","article-title":"Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: a systematic review and Bayesian network meta-analysis","volume":"78","author":"Iketani R","year":"2020","unstructured":"Iketani R, Furushima D, Imai S, Yamada H. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: a systematic review and Bayesian network meta-analysis. Parkinsonism Relat. Disord. 78, 82\u201390 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/08919887231154933","article-title":"Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson's disease psychosis: systematic review and network meta-analysis","volume":"36","author":"Yunusa I","year":"2023","unstructured":"Yunusa I, Rashid N, Seyedin R, Paratane D, Rajagopalan K. Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson's disease psychosis: systematic review and network meta-analysis. J. Geriatr. Psychiatry Neurol. 36(5), 417\u2013432 (2023).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.genhosppsych.2024.02.008","article-title":"Second-generation antipsychotics for Parkinson's disease psychosis: a systematic review and network meta-analysis","volume":"87","author":"Srisurapanont M","year":"2024","unstructured":"Srisurapanont M, Suradom C, Suttajit S, Kongsaengdao S, Maneeton B. Second-generation antipsychotics for Parkinson's disease psychosis: a systematic review and network meta-analysis. Gen. Hosp. Psychiatry 87, 124\u2013133 (2024).","journal-title":"Gen. Hosp. Psychiatry"},{"key":"e_1_3_6_35_2","unstructured":"Parkinson's Foundation. Statistics. (2025). Available from: https:\/\/www.parkinson.org\/Understanding-Parkinsons\/Statistics"},{"issue":"1","key":"e_1_3_6_36_2","article-title":"Risk of hospital admission in patients with Parkinson's disease associated psychosis (1991\u20132010) [abstract]","volume":"35","author":"Stang C","year":"2020","unstructured":"Stang C, Hajeb M, Camerucci E Risk of hospital admission in patients with Parkinson's disease associated psychosis (1991\u20132010) [abstract]. Mov. Disord. 35(Suppl. 1), Abstract 782 (2020).","journal-title":"Mov. Disord."},{"key":"e_1_3_6_37_2","unstructured":"ResDAC. Strengths and limitations of CMS administrative data in research. https:\/\/resdac.org\/articles\/strengths-and-limitations-cms-administrative-data-research"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:17:52Z","timestamp":1764760672000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.57264\/cer-2025-0129"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0129","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"e250129"}}